FORMA Therapeutics and the University of Oxford Announce Multi-Year Cross-Border Collaboration

Choate represented FORMA Therapeutics in its recent cross-border collaboration and license agreement with the University of Oxford under which the parties will identify, validate and develop deubiquitinating enzyme (DUB) inhibitors for the treatment of neurodegenerative diseases.

The FORMA/Oxford collaboration will bring together Oxford’s world class expertise in disease molecular pathology and DUB biology, (including through the Alzheimer’s Research UK Oxford Drug Discovery Institute (ODDI) and the Oxford Parkinson’s Disease Centre (OPDC)), and FORMA’s deep expertise in small molecule drug design and development.